电阻抗肌电图检测面肩肱型肌营养不良症12至24个月疾病进展
结果显示EIM相位参数重测信度优秀,与FSHD复合结局指标强相关,且在12至24个月期间可检测到显著下降,提示其作为FSHD临床试验生物标志物的潜力。
要点
- EIM相位参数在FSHD患者中重测信度优秀(ICC≥0.94)。
- EIM相位与FSHD-COM和MFM1强相关,电抗相关性中等。
- EIM相位在12至24个月期间显著下降,电抗变化不显著。
核心结论
- EIM相位参数可靠、有效且对12至24个月内的病情变化敏感,支持其作为FSHD临床试验生物标志物的潜在用途。
研究设计与样本
- 对6块肌肉(三角肌、肱二头肌、肱三头肌、股外侧肌、胫骨前肌、腓肠肌内侧头)双侧进行EIM检测。
主要发现
- 所有EIM结局的重测信度优秀(ICC≥0.94)。
- 相位参数与FSHD-COM强相关(r≤-0.69),与MFM1强相关(r≥0.75);电抗与FSHD-COM中等相关(r≥-0.41),与MFM1中等相关(r≤0.44)。
- 12个月时相位和相位比出现平均下降,例如50 kHz下为-0.25(95%CI -0.45至-0.05),并持续至24个月:50 kHz下为-0.66(95%CI -0.92至-0.40),100 kHz下为-0.65(95%CI -0.87至-0.44),均p<0.0001。
- 电抗变化较小且不显著:50 kHz下为-0.21(95%CI -0.44至0.02),100 kHz下为-0.13(95%CI -0.35至0.10)。
关键数值与推荐
- EIM相位参数重测信度ICC≥0.94。
- 相位与FSHD-COM的相关系数r≤-0.69,与MFM1的相关系数r≥0.75。
- 24个月时50 kHz相位下降-0.66(95%CI -0.92至-0.40),100 kHz相位下降-0.65(95%CI -0.87至-0.44),均p<0.0001。
临床怎么用
- EIM相位参数可作为FSHD临床试验中监测疾病进展的非侵入性生物标志物,尤其适用于早期试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Targeted therapies for facioscapulohumeral muscular dystrophy (FSHD) are progressing through clinical trials. Electrical impedance myography (EIM) provides a noninvasive biomarker of muscle composition that may be valuable especially in early phase trials. This study evaluated EIM data from a multicenter FSHD cohort over 24 months. METHODS: Adult patients with FSHD at 8 sites underwent EIM in 6 muscles bilaterally (deltoid, biceps, triceps, vastus lateralis, tibialis anterior, and medial gastrocnemius). EIM outcomes phase and reactance (50 and 100 kHz [kilohertz] frequencies) and 50 of 211 kHz phase ratio were evaluated for reliability, correlations with clinical measures, and sensitivity to change. RESULTS: One hundred fifty-seven patients (53% male patients) were included. Test-retest reliability was excellent for all EIM outcomes (intraclass correlation coefficient [ICC] ≥0.94). Phase outcomes strongly correlated with the FSHD-composite outcome measure (FSHD-COM; r ≤ -0.69) and Motor Function Measure Domain 1 (MFM1; r ≥ 0.75); reactance outcomes exhibited moderate correlations with the FSHD-COM (r ≥ -0.41) and MFM1 (r ≤ 0.44). Mean declines in phase and phase ratio were apparent at 12 months (eg, -0.25, 95% confidence interval [CI] = -0.45 to -0.05 at 50 kHz), and further progressed through 24 months (-0.66, 95% CI = -0.92 to -0.40] at 50 kHz and -0.65 [95% CI = -0.87 to -0.44] at 100 kHz; both p < 0.0001). Reactance changes were smaller and not significant: -0.21 (95% CI = -0.44 to 0.02) at 50 kHz and -0.13 (95% CI = -0.35 to 0.10) at 100 kHz. INTERPRETATION: EIM phase outcomes are reliable, valid, and sensitive to change over 12 to 24 months, supporting their potential utility as biomarkers in FSHD clinical trials. ANN NEUROL 2026;99:1545-1554.
引用
- Mul K, McDermott MP, Butterfield RJ, et al. Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy. Ann Neurol. 2026. PMID: 41724900. doi:10.1002/ana.78182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。